Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1987-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.84.14.5024PMID 3110781PMCID PMC305239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum.

  2009cited by this paper
• cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.

  1987cited by this paper
• Beyond ANOVA, basics of applied statistics

  1987cited by this paper
• Acute leukemia following cisplatin for bladder cancer.

  1986cited by this paper
• Mechanisms in Tobacco Carcinogenesis

  1986cited by this paper
• Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

  1986cited by this paper
• Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

  1986cited by this paper
• Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers.

  1985cited by this paper
• Occurrence of second primary malignancies in man--a second look.

  1985cited by this paper
• Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage.

  1985cited by this paper
• The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.

  1985cited by this paper
• Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis.

  1985cited by this paper
• Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography.

  1985cited by this paper
• Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

  1985cited by this paper
• High-dose cisplatin in hypertonic saline.

  1984cited by this paper
• The use of carcinogen-DNA adduct antisera for quantitation and localization of genomic damage in animal models and the human population.

  1984cited by this paper
• Leukemia following treatment of germ cell tumors in men.

  1984cited by this paper
• Selective modification of glutathione metabolism.

  1983cited by this paper
• Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

  1982cited by this paper
• Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation.

  1982cited by this paper
• A pilot project in molecular cancer epidemiology: determination of benzo[a]pyrene--DNA adducts in animal and human tissues by immunoassays.

  1982cited by this paper
• DNA repair in bacteria and mammalian cells.

  1979cited by this paper
• Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat.

  1979cited by this paper
• DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity.

  1979cited by this paper
• Trend and homogeneity analyses of proportions and life table data.

  1977cited by this paper
• Subcellular Components: Preparation and Fractionation

  1972cited by this paper

• Treatment of human cells with the anti-cancer drug cisplatin results in the caspase-dependent release of adduct-containing cell-free DNA.

  2025cites this paper
• Chemotherapy boosts anti-angiogenic and anti-PD-1 combination therapy through activation of cCAS-STING pathway in colon cancer.

  2025cites this paper
• The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy

  2024cites this paper
• Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients’ Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome

  2024cites this paper
• Quantifying Intracellular Platinum Accumulation Using Inductively Coupled Mass Spectrometry

  2024cites this paper
• DNA Adducts in Cancer Chemotherapy.

  2024cites this paper
• Emerging and established therapies for chemotherapy-induced ototoxicity

  2023cites this paper
• Comprehensive network analysis of dysregulated genes revealed MNX1‐AS1/hsa‐miR‐4697‐3p/HOXB13 axis in ovarian cancer chemotherapy response

  2022cites this paper
• Uev1A promotes breast cancer cell migration by up-regulating CT45A expression via the AKT pathway

  2021cites this paper
• Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients

  2021cites this paper
• Applications of Adductomics in Chemically Induced Adverse Outcomes and Major Emphasis on DNA Adductomics: A Pathbreaking Tool in Biomedical Research

  2021cites this paper
• Pharmacogenomics for the efficacy of platinum-based chemotherapy: Old drugs, new integrated perspective.

  2020cites this paper
• Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy

  2020cites this paper
• Uev1A Promotes Breast Cancer Cell Migration and EMT by Up-Regulating CT45A Expression via the AKT Pathway

  2020cites this paper
• Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.

  2018cites this paper
• OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells

  2018cites this paper
• A diagnostic microdosing approach to investigate platinum sensitivity in non‐small cell lung cancer

  2017cites this paper
• HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell.

  2017cites this paper
• Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect.

  2016cites this paper
• Exploring mTOR signalling as a targeted approach against ovarian cancer

  2016influential citation
• DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine

  2016cites this paper
• Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer

  2015cites this paper
• Human Monocytes in the Presence of Interferons Alpha2a and Gamma Are Potent Killers of Serous Ovarian Cancer Cell Lines in Combination with Paclitaxel and Carboplatin

  2015cites this paper
• Measuring DNA damage and associated epigenetic changes genome-wide in cells following exposure to platinum analogue chemotherapeutic drugs

  2014cites this paper
• Prediction of individual response to anticancer therapy: historical and future perspectives

  2014cites this paper
• Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

  2013cites this paper
• Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy: A Three-Dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method

  2013cites this paper
• Platinum-Based Chemotherapy : A Three-Dimensional ( 3-D ) , Polyacrylamide Gel-Based DNA Microarray Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with

  2013cites this paper
• Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.

  2012cites this paper
• Modulatory effects of gentisic acid against genotoxicity and hepatotoxicity induced by cyclophosphamide in Swiss albino mice

  2012cites this paper
• Cisplatin GG-crosslinks within single-stranded DNA: origin of the preference for left-handed helicity.

  2012cites this paper
• Xeroderma pigmentosum complementation group C single‐nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression‐free survival in advanced ovarian cancer

  2012cites this paper
• Molecular mechanisms of cisplatin resistance in bladder cancer

  2012cites this paper
• Preclinical Perspectives on Platinum Resistance

  2012cites this paper
• Progress in Personalizing Chemotherapy for Bladder Cancer

  2012cites this paper
• Clinical Perspectives on Platinum Resistance

  2012cites this paper
• Clinical Pharmacokinetics and Administration of Established Platinum Drugs

  2012cites this paper
• Platinum-DNA interstrand crosslinks: molecular determinants of bending and unwinding of the double helix.

  2012cites this paper
• ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

  2011cites this paper
• A microdosing approach for characterizing formation and repair of carboplatin–DNA monoadducts and chemoresistance

  2011cites this paper
• Core cross-linked block ionomer micelles as pH-responsive carriers for cis-diamminedichloroplatinum(II).

  2011cites this paper
• Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

  2010cites this paper
• Pt(II) and Ag(I) complexes with acesulfame: crystal structure and a study of their antitumoral, antimicrobial and antiviral activities.

  2010cites this paper
• Quantitative methods for studying DNA interactions with chemotherapeutic cisplatin

  2010cites this paper
• Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transactivation

  2009cites this paper
• DNA Repair Proteins and Telomerase Reverse Transcriptase in the Cochlear Lateral Wall of Cisplatin-Treated Rats

  2009cites this paper
• Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.

  2009cites this paper
• DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells

  2009cites this paper
• The influence of cisplatin on the gas-phase dissociation of oligonucleotides studied by electrospray ionization tandem mass spectrometry

  2009cites this paper
• Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.

  2009cites this paper
• Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach.

  2009cites this paper
• Identification by NMR spectroscopy of the two stereoisomers of the platinum complex [PtCl2(S-ahaz)] (S-ahaz = 3(S)-aminohexahydroazepine) bound to a DNA 14-mer oligonucleotide. NMR evidence of structural alteration of a platinated A x T-rich 14-mer DNA duplex.

  2009cites this paper
• Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity

  2009cites this paper
• Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA

  2009cites this paper
• Development of an ultra performance LC/MS method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts

  2009cites this paper
• High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.

  2008cites this paper
• Cisplatin induces cytoplasmic to nuclear translocation of nucleotide excision repair factors among spiral ganglion neurons.

  2008cites this paper
• Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels above 120 G/DL with Erythropoietin vs above 100 G/DL without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer: A Gynecologic Oncology Group Study

  2008cites this paper
• Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

  2008influential citation
• Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.

  2008cites this paper
• Mechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase

  2008cites this paper
• Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB.

  2007cites this paper
• Prognostic factors and predictive tests in the treatment of head and neck squamous cell carcinoma

  2007cites this paper
• Expression of EGFR and p-EGFR correlates with cisplatin sensitivity in oral squamous cell carcinomas

  2007cites this paper
• The first pure LambdaHT rotamer of a complex with a cis-[metal(nucleotide)2] unit: a cis-[Pt(amine)2(nucleotide)2] LambdaHT rotamer with unique molecular structural features.

  2007cites this paper
• Multiple end‐point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing

  2007cites this paper
• Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.

  2007cites this paper
• Synthesis and X-ray structure of the dinuclear platinum(II) complex with saccharin {K[Pt(sac)3(H2O)] · H2O}2: Studies on its antiproliferative activity in aqueous solution

  2007cites this paper
• A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.

  2007cites this paper
• Mechanisms of resistance to cisplatin and carboplatin.

  2007cites this paper
• Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

  2007cites this paper
• Development of a liquid chromatography-electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples.

  2007cites this paper
• Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy

  2007cites this paper
• Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.

  2007cites this paper
• Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer

  2006cites this paper
• Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy

  2006cites this paper
• GENE EXPRESSION KINETICS AND PROTEIN DISTRIBUTION OF NUCLEOTIDE EXCISION REPAIR FACTORS IN THE INNER EAR AS A FUNCTION OF cis-DIAMMINEDICHLOROPLATINUM-II DNA DAMAGE

  2006cites this paper
• Prediction of treatment outcome by cisplatin‐DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin‐radiation (RADPLAT)

  2006cites this paper
• Acceleration ofTelomere Loss by Chemotherapy Is Greater in Older Patients with LocallyAdvanced Head and Neck Cancer

  2006cites this paper
• Speciation studies of cis-platin adducts with DNA nucleotides via elemental specific detection (P and Pt) using liquid chromatography-inductively coupled plasma-mass spectrometry and structural characterization by electrospray mass spectrometry

  2006cites this paper
• Exploring the universality of unusual conformations of the 17-membered Pt(d(G*pG*)) macrochelate ring. Dependence of conformer formation on a change in bidentate carrier ligand from an sp3 to an sp2 nitrogen donor.

  2005cites this paper
• Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.

  2005cites this paper
• Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.

  2005cites this paper
• Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma.

  2005cites this paper
• Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R.

  2005cites this paper
• Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.

  2005cites this paper
• Phase I Clinical Trial of the Flavonoid Quercetin: Pharmacokinetics and Evidence for in Vivo Tyrosine Kinase Inhibition1

  2005cites this paper
• Marked dependence on carrier-ligand bulk but not on carrier-ligand chirality of the duplex versus single-strand forms of a DNA oligonucleotide with a series of G-Pt(II)-G intrastrand cross-links modeling cisplatin-DNA adducts.

  2005cites this paper
• Telomere Dynamics and Chemotherapy in Aging and Cancer

  2005cites this paper
• Amifostine Antioxidant Effect on Serum of Rats Treated with Cyclophosphodamide

  2005cites this paper
• Methodologies for Measuring Carcinogen Adducts in Humans1

  2005cites this paper
• Phase I Clinical Trial of the Flavonoid Quercetin : Pharmacokinetics and Evidence for in Vivo Tyrosine Kinase Inhibition 1

  2005cites this paper
• Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial

  2004cites this paper
• A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia

  2004cites this paper
• Quantition of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration

  2004cites this paper
• Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo.

  2004cites this paper
• Antibodies against cisplatin-modified DNA and cisplatin-modified (di) nucleotides

  2004cites this paper
• Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer.

  2004cites this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cites this paper
• WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

  2004cites this paper